Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 13 of 13« First...910111213

New cholesterol methods needed in wake of failed drugs, heart researchers say

New ways of controlling cholesterol, including possibly directly injecting “good” HDL cholesterol into patients, need to be studied following the failure of promising treatments from Eli Lilly, Pfizer Inc and Roche Holding AG, according to top heart researchers. Lilly in October halted a 12,000-patient study of its experimental drug evacetrapib, an oral medication that in […]

Read More »

Semaglutide Demonstrated Superior Improvements in Glycemic Control vs Placebo in Adults with Type 2 Diabetes

BOSTON, April 2, 2016 /PRNewswire/ — Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide, administered once weekly, significantly improved glycemic control compared to placebo in adults with type 2 diabetes previously managed with diet and exercise alone. Results from the SUSTAIN 1 […]

Read More »

Novartis takes Entresto case to U.S. cardiologist meeting

Novartis took its campaign to invigorate sluggish sales of its new heart-failure medicine Entresto to a U.S. cardiologists meeting on Saturday, telling attendees that even clinically stable patients can benefit from the drug.   Novartis, which forecasts Entresto will eventually hit $5 billion in annual sales, has seen its introduction last year get off to […]

Read More »

Europe gives green light to first gene therapy for children

The world’s first life-saving gene therapy for children, developed by Italian scientists and GlaxoSmithKline, has been recommended for approval in Europe, boosting the pioneering technology to fix faulty genes.   The European Medicines Agency (EMA) said on Friday it had endorsed the therapy, called Strimvelis, for a tiny number of children with ADA Severe Combined […]

Read More »

Array Bio ends late-stage study of ovarian cancer drug

Array BioPharma Inc said it was abandoning a late-stage study testing its experimental ovarian cancer drug, after an interim analysis showed the trial would likely fail.

Read More »

Turkish prosecutor opens bribery probe into drugmaker Novartis

The Ankara Chief Prosecutor has launched an investigation into the Turkish unit of Swiss drugmaker Novartis after allegations the company benefited from bribery.

Read More »

Drug shortages prompt question: are some medicines too cheap?

Shortages of essential drugs are becoming increasingly frequent globally, prompting the WHO to suggest minimum prices may be needed to keep some products on the market.

Read More »

Pfizer Becomes Victim of Pre-April Fool’s Day Press Release Scam

April 1, 2016 By Mark Terry, Breaking News Staff   In what seems to be an early April Fool’s Day joke, a fake website yesterday released a press release under Pfizer (PFE)’s name. The Washington Post then published a story based on the press release, which it has now removed and retracted. The press […]

Read More »

Janssen R&D Discontinues Fulranumab Phase III Program with Amgen

Janssen R&D Discontinues Fulranumab Phase III Program; Terminates Agreement with Amgen   April 1, 2016By Alex Keown, Breaking News Staff   TITUSVILLE, N.J. — Janssen Research & Development, a subsidiary of Johnson & Johnson (JNJ), terminated its Phase III development program for fulranumab in osteoarthritis pain due to a “strategic portfolio prioritization,” the company […]

Read More »

Drugmakers say Japan R&D spending at risk after government forces price cuts

Global drugmakers said they could cut research spending in Japan due to new rules requiring them to slash prices on some blockbuster drugs, including Gilead Sciences Inc’s highly effective but expensive hepatitis C drug, Sovaldi. Drugmakers such as the Japanese arms of Pfizer Inc and Eli Lilly and Co said the change, which could as […]

Read More »

Page 13 of 13« First...910111213

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom